Asia Biomaterials (Wuhan) Co., Ltd. is a core medical device enterprise in China Optics Valley Biocity. It has been recognized as a Hubei Provincial Specialized, Refined, Differential and Innovative (SRDI) Enterprise, a "Golden Seed" Enterprise for IPO cultivation designated by the Hubei Provincial Office for Enterprise Listing, and a Wuhan Gazelle Enterprise. The Group comprises four holding subsidiaries and three independent business divisions, including two National High-Tech Enterprises.

Asia Biomaterials Group operates world-class GMP-compliant intelligent manufacturing facilities equipped with Class 10,000 cleanrooms. Its headquarters, new product base and intelligent manufacturing center cover a total floor area of approximately 23,000 square meters. The Group has established the International Joint Laboratory for High-End Biomaterial Devices, together with four provincial- and ministerial-level R&D platforms: the Hubei Research Institute of Bioactive Material Devices, the Hubei Engineering Research Center for Oral and Maxillofacial Medical Devices and Equipment, the Hubei Provincial SME Technology Center, and the Wuhan Enterprise R&D Center. As the world-leading production base for calcium phosphate bioactive materials, the Group has also established overseas collaborative R&D centers and innovation bases in the United States, Australia, South Korea, and countries participating in the Belt and Road Initiative (BRI).

The company has led and undertaken numerous major national research programs, including key special projects under the National Key R&D Program of China, major innovation projects under the Open Competition ("Jiebang Guashuai") initiative jointly launched by the Ministry of Industry and Information Technology (MIIT) and the National Medical Products Administration (NMPA), projects under the National High-Tech R&D Program (863 Program), the National Science and Technology Support Program, and the Ministry of Science and Technology's Intergovernmental International Science and Technology Cooperation Program. These achievements reflect the company’s leading capabilities in innovation, research translation, and commercialization in the field of high-end biomaterials and medical devices.